ArticlePakistan journal of medical sciences2025
Expression of PD-L1 in pleural effusion of advanced lung adenocarcinoma and its relationship with DNA ploidy.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Programmed death receptor-1 (PD-1) negatively regulates antigen receptor signaling upon binding to its ligands, programmed death-ligand 1 or 2 (PD-L1/2), enabling tumor cells to evade immune surveillance. This study aimed to investigate the expression of PD-L1 in tumor cells present in pleural effusion (PE) from lung adenocarcinoma (LUAD) with metastasis and its relationship with DNA ploidy. Furthermore, it sought to assess whether high PD-L1 expression enhances tumor cell proliferation and invasiveness. Methodology: This was a retrospective study. PE specimens were collected from patients diagnosed with stage IV LUAD, meeting the malignant tumor UICC (Union for International Cancer Control) TNM staging system, at the Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital between July 2021 to December 2023. The expression of PD-L1 in LUAD cells in PE was detected using immunocytochemistry, and the invasiveness of tumor cells with varying PD-L1 expression levels was evaluated through DNA quantitative analysis. Results: The positive expression rate of PD-L1 in PE from advanced LUAD was 60.22%. Variations in PD-L1 expression were associated with the mean DNA index values exceeding 2.5 among the top 20 tumor cells analyzed. Conclusion: Compared with the non-expression group, the low-expression PD-L1 group demonstrated greater tumor cell invasiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.